Monograph
L01DB02 - Daunorubicin |
Propably not porphyrinogenic |
PNP |
Rationale
Substrat of CYP3A4, but no indications of CYP-inducing or inhibiting capacity.
Chemical description
Daunorubicin is an antineoplastic anthracycline antibiotic.
Therapeutic characteristics
Daunorubicin is used in the treatment of acute lymphoblastic and myeloid leucemias, often in combination with other anti-neoplastic drugs. Administered as iterated intravenous infusions. Diarrhoea is a common adverse reaction of daunorubicin that can be confused with symptoms of an acute porphyric attack.
Metabolism and pharmacokinetics
Daunorubicin is rapidly metabolised in the liver by NADPH cytochrome P450 reductase. Baumhakel (2001) found that daunorubisin had only a minor inhibitory effect on human CYP3A4. Substrate of CYP3A4. No interactions described pointing to interference with CYP-metabolism of other drugs. Not listed as CYP 3A4 or 2C9 -inducer or inhibitor by Rendic (2002).
IPNet drug reports
No.
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.
|
|
| 2. | Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Int J Clin Pharmacol Ther 2001;39(12):517-28.
Baumhäkel M, Kasel D, et al. |
11770832 |
| * | Drug reference publications | |
| 3. | McEvoy GK, editor. Daunorubicin. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (04.05.10).
|
|
| 4. | Sweetman SC, editor. Martindale: The complete drug reference. Daunorubicin. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 5. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Cerubidin.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Luxembourg
Serbia© NAPOS 2024